1-3 of 3
Jaya Srivastava
Close
Sort by
Journal Articles

Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy

Clinical Trials & Observations
Philip A. Thompson, Jaya Srivastava, Christine Peterson, Paolo Strati, Jeffrey L. Jorgensen, Tyler Hether, Michael J. Keating, Susan M. O’Brien, Alessandra Ferrajoli, Jan A. Burger, Zeev Estrov, Nitin Jain, William G. Wierda
Journal: Blood
Blood (2019) 134 (22): 1951–1959.
https://doi.org/10.1182/blood.2019001077
Published: 2019
Includes: Supplemental data
Journal Articles

Moffitt Cancer Center 2-Year Single-Institution Experience with Next-Generation Sequencing Minimal Residual Disease Detection: Clinical Utility, Application, and Correlation with Outcomes in Plasma Cell and Lymphoid Malignancies

Mohammad O Hussaini, MD, Jaya Srivastava, PhD, Lik Wee Lee, PhD, Taiga Nishihori, MD, Bijal Shah, MD, Melissa Alsina, MD, Rachid Baz, MD, Javier Pinilla Ibarz, MD PhD, Kenneth H. Shain, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4654.
https://doi.org/10.1182/blood-2019-129846
Published: 2019
Journal Articles

Undetectable-Minimal Residual Disease (U-MRD6) (10 -6 sensitivity) Is Associated with Best Progression-Free Survival for Patients Who Achieve Bone Marrow Undetectable MRD4 (10 -4 sensitivity) with First-Line FCR

Philip A. Thompson, MBBS, Jaya Srivastava, Paolo Strati, MD, Jeffrey L. Jorgensen, MD PhD, Joyce Breaker, Tyler Hether, Michael J Keating, MBBS, Susan M. O'Brien, MD, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD, Zeev E. Estrov, MD, Nitin Jain, MD, William G. Wierda, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3137.
https://doi.org/10.1182/blood-2018-99-117864
Published: 2018